Source - RNS
RNS Number : 6624K
Premaitha Health PLC
23 September 2016


Premaitha Health plc

("Premaitha" or the "Company")


Notice of results & appointment of broker


Manchester, UK - 23 September 2016 - Premaitha Health plc (AIM: NIPT), developer of the leading CE-marked complete non-invasive prenatal screening system, makes the following announcements:


Notice of Results

Premaitha will publish its financial results for the year ended 31 March 2016 by Friday 30 September  2016. The Company will recognise in these accounts a significant increase in the provision relating to its litigation with Illumina in respect of the robust defence being mounted by Premaitha. The annual report will be posted on the Company's website and distributed to shareholders shortly thereafter, along with an AGM notice.


Appointment of Broker

Premaitha also announces that it has appointed finnCap Ltd as sole broker to the Company. Cairn Financial Advisers LLP remains as Nominated Adviser to the Company.


The information contained within this announcement constitutes inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.


For more information, please contact:


Premaitha Health plc

Tel: +44 (0) 161 667 6865

Dr Stephen Little, Chief Executive Office


Barry Hextall, Chief Financial Officer


Joanne Cross, Head of Marketing


[email protected]




Cairn Financial Advisers LLP (Nomad)

Tel: +44 (0) 20 7148 7900

Liam Murray




finnCap (Broker)

Tel: +44 (0) 20 7220 0500

Adrian Hargrave / Scott Mathieson (Corporate Finance)


Tony Quirke (Corporate Broking)




Vigo Communications

Tel: +44 (0) 20 7830 9704

Ben Simons / Fiona Henson / Antonia Pollock


[email protected]




About Premaitha


Premaitha is a molecular diagnostics company which uses the latest advances in DNA analysis technology to develop safer, faster and regulatory approved non-invasive screening tests for pregnant women.


Premaitha's lead test - the IONA® test - was launched in February 2015 and is the leading CE-marked complete system which estimates the risk of a fetus being affected with Down's syndrome or other genetic conditions. The IONA® test is performed on the mother's blood sample - which contains traces of fetal DNA - and then analysed using next generation DNA sequencing technology from ThermoFisher Scientific.


Unlike existing prenatal screening methods, due to its high level of accuracy, the IONA® test can significantly reduce the number of women subjected to unnecessary stressful and invasive follow up diagnostic procedures which are costly, resource intensive and carry a risk of miscarriage.


Non-invasive prenatal screening is an emerging, multi-billion dollar global market and Premaitha's CE-marked complete system enables laboratories and healthcare practitioners to offer an approved, non-invasive prenatal screening solution in-house. 


Premaitha is based in Manchester Science Park, United Kingdom and its shares trade on the AIM market of the London Stock Exchange (AIM: NIPT). For further information please visit Follow us on twitter @PremaithaHealth.

This information is provided by RNS
The company news service from the London Stock Exchange